Robert Lechleider Acquires 15,805 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider bought 15,805 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average cost of $9.48 per share, with a total value of $149,831.40. Following the acquisition, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Immunome Trading Up 3.4 %

Shares of Immunome stock opened at $11.53 on Wednesday. The firm has a market cap of $719.70 million, a PE ratio of -1.42 and a beta of 1.82. The stock has a 50 day moving average of $12.49 and a 200 day moving average of $13.55. Immunome, Inc. has a 12 month low of $6.93 and a 12 month high of $30.96.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on IMNM shares. Piper Sandler dropped their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Stephens assumed coverage on Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $28.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC purchased a new stake in Immunome during the second quarter valued at $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Immunome in the 2nd quarter worth $97,000. Arizona State Retirement System increased its holdings in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after buying an additional 918 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Immunome during the 3rd quarter valued at about $219,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after acquiring an additional 4,129 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.